SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

British Journal of Cancer

Volumn 87, Issue 6, 2002, Pages 630-634

  Boulay, Jean Louis ^a   Mild, G ^a   Lowy, A ^b   Reuter, J ^a   Lagrange, M ^a,c   Terracciano, L ^a   Laffer, U ^b   Herrmann, R ^a   Rochlitz, C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Colorectal cancer; Predictive marker; Signalling; SMAD; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FLUOROURACIL; MITOMYCIN; SMAD PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 18Q; COLORECTAL CANCER; CONTROLLED STUDY; DIPLOIDY; DISEASE MARKER; FEMALE; GENE DELETION; GENE DOSAGE; GENE LOCATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR BIOPSY;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 18; COLORECTAL NEOPLASMS; DNA PRIMERS; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SURVIVAL RATE; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0037048331     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600511     Document Type: Article

References (30)

1. Blobe GC, Schieman WP, Lodish HF (2000) Role of the transformiong growth factor β in human disease. N Engl J Med 342: 1350-1358
2. Boulay JL, Reuter J, Ritschard R, Terracciano L, Herrmann R, Rochlitz C (1999) Gene dosage by quantitative real-time PCR. Biotechniques 27: 228-232
3. Boulay JL, Mild G, Reuter J, Lagrange M, Terracciano L, Lowy A, Laffer U, Orth B, Metzger U, Stamm B, Martinoli S, Herrmann R, Rochlitz C (2001) Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7. Genes Chrom Cancer 31: 240-247
4. Derinck R, Gelbart WM, Harland RM, Heldin CH, Kern SE, Massagué J, Melton DA, Mlodzik M, Padgett RW, Roberts AB, Smith J, Thomsen GH, Vogelstein B, Wang XF (1996) Nomenclature: vertebrate mediators of TGFβ family signals. Cell 87: 173
5. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L (1996) MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543-552
6. Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumour suppressor gene at human chromosome 18q21.1. Science 271: 350-353
7. Houghton JA, Harwood FG, Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via Fas signalling. Proc Natl Acad Sci USA 94: 8144-8149
8. Hsing AY, Kadomatsu K, Bonham MJ, Danielpour D (1996) Regulation of apoptosis induced transforming growth factor-beta1 in nontumorigenic and tumorigenic rat prostatic epithelial cell lines. Cancer Res 56: 5146-5149
9. Jen J, Kim H, Piantadosi S, Liu OF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213-221
10. Jernwall P, Mäkinen MI, Karttunen TJ, Mäkelä J, Vihko P (1999) Loss of Heterozygocity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 79: 903-908
11. Kretschmar M, Massagué J (1999) SMADs: mediators and regulators of TGF-beta signalling. Curr Opin Genet Dev 8: 103-111
12. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T ValidireP, Muleris M, Girodet J, Salmon RJ (1992) Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102: 1136-1141
13. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338
14. Martínez-López E, Abad A, Font A, Monzó M, Ojanguren I, Pifarré A, Sánchez JJ, Martín C, Rosell R (1998) Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114: 1180-1187
15. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P (1992) Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903
16. Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nature Genetics 15: 417-474
17. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389: 631-635
18. Newfeld SJ, Wisotzkey RG, Kumar S (1999) Molecular evolution of a developmental pathway: phylogenetic analyses of transforming growth factor-β family ligands, receptors and smad signal transducers. Genetics 152: 783-795
19. Raftery LA, Twombly V, Wharton K, Gelbart WM (1995) Genetic screens to identify, elements of the decapentaplegic signalling pathway in Drosophila. Genetics 139: 241-254
20. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969
21. Reiss M, Muñoz-Antonia T, Cowan JM, Wilkins PC, Zhou ZL, Vellucci VF (1993) Resistance of human squamous carcinoma cells to transforming growth factor beta1 is a recessive trait. Proc Natl Acad Sci USA 90: 6280-6284
22. Roberts AB, Sporn MB (1993) The transforming growth factor-betas. In: Handbook of experimental pharmacology: peptide growth factors and their receptors, Sporn MB, Roberts AB (eds) pp 419-472. Berlin-Heidelberg: Springer-Verlag
23. Röijer E, Morén A, ten Dijke P, Stenman G (1998) Assignment of the SMAD-7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridization. Cytogenet Cell Genet 81: 189-190
24. Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, Padgett RW (1996) Caenorhabditis elegans genes sma-2, sma-3 and sma-4 define a conserved family of transforming growth factor beta pathway components. Proc Natl Acad Sci USA 93: 790-794
25. Swiss Group for Clinical Cancer Research SAKK (1995) Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. The Lancet 345: 349-353
26. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genet 13: 343-346
27. Venter C et al (2001) The sequence of the human genome Science 291: 1304-1345
28. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumour development. N Engl J Med 319: 525-532
29. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
30. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson III AB, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196-1206